MRK240726P126000
- 1.05
- -0.87-45.31%
Merck & Co Newsroom
Preventive monoclonal antibody from Merck (MRK.US) achieves positive results, used for preventing infant RSV infection.
Merck (MRK.US) announced that the investigational respiratory syncytial virus (RSV) prophylactic monoclonal antibody clesrovimab (MK-1654) has obtained positive results in phase 2b/3 clinical trials.
Acquiring the company for over 1.3 billion US dollars! Merck's (MRK.US) new small-molecule cancer drug has entered phase 3 clinical trials in China.
According to the latest announcement by China's drug clinical trial registration and information disclosure platform, Merck (MRK.US) has initiated a Phase III clinical study for a new oral drug, MK-3543 (bomedemstat), for the treatment of primary thrombocytosis.
Merck & Co To Go Ex-Dividend On September 16th, 2024 With 0.77 USD Dividend Per Share
Merck Competes With Sanofi/AstraZeneca As Its RSV Treatment Drug Meets Primary Goal In Late-Stage Study In Infants
Merck Declares $0.77 Dividend
Express News | Merck & Co Inc - Has Declared a Quarterly Dividend of $0.77 per Share of Company's Common Stock for Q4 of 2024.
Express News | Merck Announces Fourth-Quarter 2024 Dividend
Merck & Co., Inc. (NYSE:MRK) Is Largely Controlled by Institutional Shareholders Who Own 78% of the Company
Merck RSV Therapy Succeeds in Infants in Challenge to Sanofi, Astra
Express News | Merck Says Its Prophylactic Monoclonal Antibody Clesrovimab For Respiratory Syncytial Virus (RSV) Disease Met Its Primary Safety And Efficacy Endpoints
Express News | Merck Reports Results From Phase 2b/3 Trial Of Clesrovimab Antibody Designed To Protect Infants From Respiratory Syncytial Virus Disease; Says Clesrovimab Met All Primary Safety And Efficacy Endpoints
Express News | Merck & Co Inc: Plans to File Data With Global Regulatory Authorities
Express News | Merck & Co Inc - Clesrovimab Met All Primary Safety and Efficacy Endpoints
Express News | Merck Announces Topline Results From Phase 2B/3 Trial of Clesrovimab (Mk-1654), an Investigational Respiratory Syncytial Virus Preventative Monoclonal Antibody for Infants
Merck & Co. Poised for Growth: Strong Q2 Performance and Promising Pipeline Fuel Buy Rating
Kamala Harris' Potential Impact on Health Care Stocks
Here Are Big Pharma's Leading Blockbuster Makers
Merck & Co Options Spot-On: On July 19th, 58,773 Contracts Were Traded, With 355.33K Open Interest
Earnings Preview: What to Expect From Merck & Co.'s Report
BMO Capital Adjusts Price Target on Merck to $150 From $148